100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
1621681-63-7Cabozantinib N-Oxide
● In Stock
| Catalogue No.: | VE007672 |
|---|---|
| CAS No.: | 1621681-63-7 |
| Mol. Formula: | C28H24FN3O6 |
| Mol. Weight: | 517.51 g/mol |
Additional information on CAS 1621681-63-7
Parent drug
CabozantinibIUPAC Name
N-[4-[(6, 7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N’-(4-fluorophenyl)-1, 1-cyclopropanedicarboxamideSynonyms
N/ADescription
It is one of impurity present in Cabozantinib, Cabozantinib is a tyrosine kinase inhibitor, which inhibits the activity of c-MET vascular endothelial growth factor receptor and other tyrosine kinases, thereby leading to reduced tumor angiogenesis motility and invasiveness. which is used in the treatment of progressive, metastatic medullary thyroid cancer, also indicated for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma.References
Schmidinger, M., & Danesi, R. (2017). Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. The Oncologist, 23(3), 306–315. https://doi.org/10.1634/theoncologist.2017-0335Request a Quote
"*" indicates required fields
Other products related to Cabozantinib impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
Cabozantinib
CAS No. 1628530-42-6
N-(4-fluorophenyl)-N-(4-((7-hydroxy-6-methoxyquinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide
Cat No. VE0021565